Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The Ecology of Antihypertensives in the United States, 1997-2017

Michael E. Johansen, View ORCID ProfileJoshua D. Niforatos, Jeremey B. Sussman
doi: https://doi.org/10.1101/2020.04.01.20050146
Michael E. Johansen
1Grant Family Medicine, OhioHealth, Columbus, OH
2Heritage College of Osteopathic Medicine at Ohio University, Dublin, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: michael.johansen@ohiohealth.com
Joshua D. Niforatos
3Department of Emergency Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joshua D. Niforatos
Jeremey B. Sussman
4Department of Internal Medicine, Division of General Medicine, University of Michigan, Ann Arbor, MI, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Antihypertensives are the most used medication type in the United States, yet there remains uncertainty about the use of different antihypertensives. We sought to characterize use of antihypertensives by and within medication class(es) between 1997-2017.

Methods A repeated cross-sectional study of 493,596 adult individuals using the 1997-2017 Medical Expenditure Panel Survey (MEPS). The Orange Book and published research were used for adjunctive information. The primary outcome was the estimated use by and within anti-hypertensive medication class(es).

Results The proportion of individuals taking any antihypertensive during a year increased from 1997 to the early 2010’s and then remained stable. The proportion of the population taking 2 or more medications declined from 2015-2017. The proportion of adults using angiotensin II receptor-blockers (ARBs) and dihydropyridine calcium channel-blockers (CCBs) increased during the study period, while angiotensin-converting enzyme inhibitors (ACE-Is) increased until 2010 after which rates remained stable. Beta-blocker use was similar to ACE-Is with an earlier decline starting in 2012. Thiazide diuretic use increased from 1997-2007, leveled off until 2014, and declined from 2015-2017. Non-dihydropyridine CCBs use declined throughout the study. ACE-Is, ARBs, CCBs, thiazide diuretics, and loop diuretics all had one dominant in-class medication. There was a clear increase in the use of losartan within ARBs, lisinopril within ACE-Is, and amlodipine within CCBs following generic conversion. Furosemide and hydrochlorothiazide started with and maintained a dominant position in their classes. Metoprolol use increased throughout the study and became the dominant beta-blocker, while atenolol peaked around 2005 and then declined thereafter.

Conclusions Antihypertensive classes appear to have a propensity to equilibrate to an individual medication, despite a lack of outcomes based research to compare medications within a class. Future research could focus on comparative effectiveness for within-class medications early in the life cycle of therapeutics that are probable to have wide spread use.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding was received.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

This data is publicly available data.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 03, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The Ecology of Antihypertensives in the United States, 1997-2017
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The Ecology of Antihypertensives in the United States, 1997-2017
Michael E. Johansen, Joshua D. Niforatos, Jeremey B. Sussman
medRxiv 2020.04.01.20050146; doi: https://doi.org/10.1101/2020.04.01.20050146
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
The Ecology of Antihypertensives in the United States, 1997-2017
Michael E. Johansen, Joshua D. Niforatos, Jeremey B. Sussman
medRxiv 2020.04.01.20050146; doi: https://doi.org/10.1101/2020.04.01.20050146

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (76)
  • Allergy and Immunology (202)
  • Anesthesia (55)
  • Cardiovascular Medicine (495)
  • Dentistry and Oral Medicine (91)
  • Dermatology (57)
  • Emergency Medicine (170)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (217)
  • Epidemiology (5749)
  • Forensic Medicine (3)
  • Gastroenterology (221)
  • Genetic and Genomic Medicine (883)
  • Geriatric Medicine (89)
  • Health Economics (233)
  • Health Informatics (777)
  • Health Policy (400)
  • Health Systems and Quality Improvement (256)
  • Hematology (105)
  • HIV/AIDS (187)
  • Infectious Diseases (except HIV/AIDS) (6581)
  • Intensive Care and Critical Care Medicine (397)
  • Medical Education (119)
  • Medical Ethics (28)
  • Nephrology (94)
  • Neurology (859)
  • Nursing (45)
  • Nutrition (143)
  • Obstetrics and Gynecology (166)
  • Occupational and Environmental Health (266)
  • Oncology (521)
  • Ophthalmology (168)
  • Orthopedics (44)
  • Otolaryngology (107)
  • Pain Medicine (48)
  • Palliative Medicine (22)
  • Pathology (150)
  • Pediatrics (257)
  • Pharmacology and Therapeutics (147)
  • Primary Care Research (116)
  • Psychiatry and Clinical Psychology (990)
  • Public and Global Health (2264)
  • Radiology and Imaging (380)
  • Rehabilitation Medicine and Physical Therapy (175)
  • Respiratory Medicine (314)
  • Rheumatology (110)
  • Sexual and Reproductive Health (83)
  • Sports Medicine (83)
  • Surgery (118)
  • Toxicology (25)
  • Transplantation (34)
  • Urology (42)